Conference
Stereotactic Radiation for the Comprehensive Treatment of Oligometastases (SABR-COMET): Extended Long-Term Outcomes
Abstract
PURPOSE: Long-term randomized data assessing the effect of ablative therapies in patients with oligometastases are lacking. The Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastases (SABR-COMET) randomized phase 2 trial was originally designed with 5 years of follow-up, but the trial was amended in 2016 to extend follow-up to 10 years. Herein we report oncologic outcomes beyond 5 years.
METHODS AND MATERIALS: …
Authors
Harrow S; Palma DA; Olson R; Gaede S; Louie AV; Haasbeek C; Mulroy L; Lock M; Rodrigues GB; Yaremko BP
Volume
114
Pagination
pp. 611-616
Publisher
Elsevier
Publication Date
November 2022
DOI
10.1016/j.ijrobp.2022.05.004
Conference proceedings
International Journal of Radiation Oncology • Biology • Physics
Issue
4
ISSN
0360-3016